Prima BioMed replaces director


By Dylan Bushell-Embling
Thursday, 13 February, 2014

Prima BioMed (ASX:PRR) has added former investment banker Pete Meyers to its board as a non-executive director.

Meyers is currently CFO of TetraLogic Pharmaceuticals, where he led the execution of its IPO in December.

Before joining TetraLogic, Meyers was an investment banker. Notable roles in the industry include co-head of global healthcare investment banking at Deutsche Bank in New York. He also held various roles at Dillon, Read & Co and Credit Suisse First Boston.

“I believe Pete’s depth of experience in the US capital markets, his network in the biotech community and his expertise advising healthcare companies will serve Prima well,” Prima Chairperson Lucy Turnbull said.

Meyers will be replacing Dr Richard Hammel, who is stepping down from the board after serving since January 2005.

Prima BioMed (ASX:PRR) shares were trading 4.08% higher at $0.051 as of around 2 pm on Tuesday.

Related News

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd